KFF survey: share of large employers covering GLP-1s for obesity falls from 43% to 33%
Key points
- Share of employers with 5,000+ workers covering GLP-1s for obesity fell from 43% to 33%
- Starbucks has halted coverage of Zepbound and Wegovy for obesity
- Some employers steer workers to direct-to-consumer pharmacies or third-party weight-loss vendors
According to KFF's annual employer health benefits survey, the share of employers with 5,000+ workers covering GLP-1 drugs for obesity fell to 33% in 2026, down from 43% a year earlier. Starbucks has halted coverage of Zepbound and Wegovy for obesity. PepsiCo and Cigna have also grappled with rising costs. Some employers steer workers to direct-to-consumer pharmacies or third-party weight-loss vendors.
Original report: USA Today ↗Edited with AI assistance. Facts are based on official sources and original reports. For information only; not legal, immigration or insurance advice.